 MONMOUTH JUNCTION, N.J., Sept. 10, 2021 PRNewswire -- CytoSorbents Corporation NASDAQ: CTSO, a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the filing of an Investigational Device Exemption IDE application to gain FDA approval to conduct the clinical study, Safe and Timely Antithrombotic Removal Direct Oral Anticoagulants STAR-D, in the United States to support FDA marketing approval. 